Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""van Grieken NCT"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 23
Tytuł:
Molecular characterization of gastric adenocarcinoma diagnosed in patients previously treated for Hodgkin lymphoma or testicular cancer.
Autorzy:
Rigter LS; Department of Gastroenterology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Snaebjornsson P; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Rosenberg EH; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Altena E; Department of Gastroenterology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Grieken NCT; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
Aleman BMP; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Kerst JM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Morton L; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Schaapveld M; Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Meijer GA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Leeuwen FE; Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Leerdam ME; Department of Gastroenterology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pokaż więcej
Corporate Authors:
PALGA group
Źródło:
PloS one [PLoS One] 2022 Jul 25; Vol. 17 (7), pp. e0270591. Date of Electronic Publication: 2022 Jul 25 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma*/genetics
Epstein-Barr Virus Infections*
Hodgkin Disease*/genetics
Stomach Neoplasms*/pathology
Testicular Neoplasms*
Brain Neoplasms ; Colorectal Neoplasms ; Herpesvirus 4, Human/genetics ; Humans ; Male ; Microsatellite Instability ; Neoplasms, Germ Cell and Embryonal ; Neoplastic Syndromes, Hereditary
SCR Disease Name:
Testicular Germ Cell Tumor; Turcot syndrome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer.
Autorzy:
Slagter AE; Department of Radiation Oncology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Caspers IA; Department of Gastrointestinal Oncology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands.
van Grieken NCT; Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands.
Walraven I; Department of Radiation Oncology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Department of Epidemiology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Lind P; Department of Oncology, Stockholm Söder Hospital, 118 83 Stockholm, Sweden.; Karolinska Institutet, Research Oncology, 171 77 Stockholm, Sweden.
Meershoek-Klein Kranenbarg E; Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Grootscholten C; Department of Gastrointestinal Oncology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Nordsmark M; Department of Oncology, Aarhus University, 8000 Aarhus, Denmark.
van Sandick JW; Department of Surgery, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Sikorska K; Department of Biometrics, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
van de Velde CJH; Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Jansen EPM; Department of Radiation Oncology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Verheij M; Department of Radiation Oncology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Department of Radiation Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
van Laarhoven HWM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
Cats A; Department of Gastrointestinal Oncology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2022 Jun 15; Vol. 14 (12). Date of Electronic Publication: 2022 Jun 15.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Diagnostic variability in the histopathological assessment of advanced colorectal adenomas and early colorectal cancer in a screening population.
Autorzy:
Smits LJH; Department of Surgery, Cancer Centre Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Vink-Börger E; Department of Pathology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.
van Lijnschoten G; PAMM Laboratories, Department of Pathology, Eindhoven, the Netherlands.
Focke-Snieders I; Department of Pathology, Reinier de Graaf Hospital, Delft, the Netherlands.
van der Post RS; Department of Pathology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.
Tuynman JB; Department of Surgery, Cancer Centre Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
van Grieken NCT; Department of Pathology, Cancer Centre Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Nagtegaal ID; Department of Pathology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.
Pokaż więcej
Źródło:
Histopathology [Histopathology] 2022 Apr; Vol. 80 (5), pp. 790-798. Date of Electronic Publication: 2022 Jan 10.
Typ publikacji:
Journal Article
MeSH Terms:
Early Detection of Cancer*
Observer Variation*
Pathologists*
Adenoma/*diagnosis
Adenoma/*pathology
Colorectal Neoplasms/*diagnosis
Colorectal Neoplasms/*pathology
Diagnosis, Differential ; Expert Testimony ; Humans ; Netherlands ; Referral and Consultation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Risk Factors for Metachronous Isolated Peritoneal Metastasis after Preoperative Chemotherapy and Potentially Curative Gastric Cancer Resection: Results from the CRITICS Trial.
Autorzy:
Caspers IA; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands.
Sikorska K; Department of Biometrics, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Slagter AE; Department of Radiation Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
van Amelsfoort RM; Department of Radiation Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Meershoek-Klein Kranenbarg E; Department of Biometrics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
van de Velde CJH; Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Lind P; Department of Oncology, Stockholm Söder Hospital, 118 83 Stockholm, Sweden.; Department of Oncology and Pathology, Karolinska Institute, 171 77 Stockholm, Sweden.
Nordsmark M; Department of Medical Oncology, Aarhus University, 8200 Aarhus, Denmark.
Jansen EPM; Department of Radiation Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Verheij M; Department of Radiation Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Department of Radiation Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
van Sandick JW; Department of Surgery, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Cats A; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
van Grieken NCT; Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Sep 15; Vol. 13 (18). Date of Electronic Publication: 2021 Sep 15.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation.
Autorzy:
Goedegebuure RSA; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.
Kleibeuker EA; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.
Buffa FM; Department of Molecular Oncology, University of Oxford, Oxford, UK.
Castricum KCM; Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.
Haider S; Department of Molecular Oncology, University of Oxford, Oxford, UK.
Schulkens IA; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.
Ten Kroode L; Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.
van den Berg J; Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.
Jacobs MAJM; Department of Gastroenterology, Cancer Center Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.
van Berkel AM; Department of Gastroenterology, Noord West Ziekenhuisgroep, Alkmaar, The Netherlands.
van Grieken NCT; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.
Derks S; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.
Slotman BJ; Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.
Verheul HMW; Department of Medical Oncology, Radboud UMC, Nijmegen, The Netherlands.
Harris AL; Department of Molecular Oncology, University of Oxford, Oxford, UK.
Thijssen VL; Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands. .
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2021 May 08; Vol. 40 (1), pp. 161. Date of Electronic Publication: 2021 May 08.
Typ publikacji:
Journal Article
MeSH Terms:
Esophageal Neoplasms/*radiotherapy
Gene Expression Regulation, Neoplastic/*radiation effects
Interferon Type I/*genetics
Membrane Proteins/*genetics
Animals ; Astrocytoma/genetics ; Astrocytoma/immunology ; Astrocytoma/metabolism ; Astrocytoma/radiotherapy ; Cell Line, Tumor ; Colonic Neoplasms/genetics ; Colonic Neoplasms/immunology ; Colonic Neoplasms/metabolism ; Colonic Neoplasms/radiotherapy ; Dose Fractionation, Radiation ; Esophageal Neoplasms/genetics ; Esophageal Neoplasms/immunology ; Esophageal Neoplasms/metabolism ; Female ; HT29 Cells ; Humans ; Immunity/radiation effects ; Interferon Type I/immunology ; Interferon Type I/metabolism ; Membrane Proteins/immunology ; Membrane Proteins/metabolism ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Random Allocation ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer.
Autorzy:
Poel D; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU Universiteit Medical Center Amsterdam, Amsterdam, the Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
Gootjes EC; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU Universiteit Medical Center Amsterdam, Amsterdam, the Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
Bakkerus L; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU Universiteit Medical Center Amsterdam, Amsterdam, the Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
Trypsteen W; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, HIV Cure Research Center, Ghent University and Ghent University Hospital, Ghent, Belgium.
Dekker H; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU Universiteit Medical Center Amsterdam, Amsterdam, the Netherlands.
van der Vliet HJ; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU Universiteit Medical Center Amsterdam, Amsterdam, the Netherlands.
van Grieken NCT; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, VU Universiteit Medical Center Amsterdam, Amsterdam, the Netherlands.
Verhoef C; Division of Surgical Oncology, Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Buffart TE; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU Universiteit Medical Center Amsterdam, Amsterdam, the Netherlands.; Department of Gastrointestinal Oncology, Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Verheul HMW; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU Universiteit Medical Center Amsterdam, Amsterdam, the Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2020 Oct; Vol. 9 (20), pp. 7558-7571. Date of Electronic Publication: 2020 Aug 30.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Biomarkers*
Transcriptome*
Colorectal Neoplasms/*diagnosis
Colorectal Neoplasms/*genetics
MicroRNAs/*genetics
Biopsy ; Clinical Decision-Making ; Colorectal Neoplasms/therapy ; Computational Biology/methods ; Diagnostic Imaging ; Disease Management ; Female ; Gene Expression Profiling/methods ; Humans ; Immunohistochemistry ; Male ; Neoplasm Grading ; Neoplasm Metastasis ; Neoplasm Staging ; Prognosis ; ROC Curve ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial.
Autorzy:
Slagter AE; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Sikorska K; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Grootscholten C; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Laarhoven HWM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Center, The Netherlands.
Lind P; Department of Oncology, Stockholm Söder Hospital, Stockholm, Sweden.; Karolinska Intitutet, Stockholm, Sweden.
Nordsmark M; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Meershoek-Klein Kranenbarg E; Department of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
van de Velde CJH; Department of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
van Grieken NCT; Department of Pathology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
van Sandick JW; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Jansen EPM; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Verheij M; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Cats A; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2020 Sep; Vol. 9 (18), pp. 6609-6616. Date of Electronic Publication: 2020 Jul 31.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Neoadjuvant Therapy/*adverse effects
Stomach Neoplasms/*drug therapy
Venous Thromboembolism/*chemically induced
Adenocarcinoma/pathology ; Adenocarcinoma/surgery ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Chemotherapy, Adjuvant/adverse effects ; Female ; Gastrectomy ; Humans ; Male ; Middle Aged ; Prospective Studies ; Risk Assessment ; Risk Factors ; Stomach Neoplasms/pathology ; Stomach Neoplasms/surgery ; Time Factors ; Treatment Outcome ; Venous Thromboembolism/diagnosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.
Autorzy:
van Helden EJ; Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands.
Elias SG; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Gerritse SL; Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands.
van Es SC; Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Boon E; Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.
Huisman MC; Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands.
van Grieken NCT; Pathology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands.
Dekker H; Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands.
van Dongen GAMS; Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands.
Vugts DJ; Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands.
Boellaard R; Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands.
van Herpen CML; Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.
de Vries EGE; Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Oyen WJG; Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, Netherlands.; The Institute of Cancer Research and The Royal Marsden Hospital, London, UK.
Brouwers AH; Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Verheul HMW; Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands.
Hoekstra OS; Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands.
der Houven van Oordt CWM; Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands. .; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands. .; Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. .; Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands. .; Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands. .; Pathology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, Netherlands. .; Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, Netherlands. .; The Institute of Cancer Research and The Royal Marsden Hospital, London, UK. .; Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. .
Pokaż więcej
Źródło:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2020 Sep; Vol. 47 (10), pp. 2481.
Typ publikacji:
Published Erratum
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer.
Autorzy:
Barat A; Centre for Systems Medicine and Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland. .
Smeets D; VIB Vesalius Research Center, KU Leuven, Leuven, Belgium.
Moran B; UCD Conway Institute, University College Dublin, Dublin, Ireland.
Zhang W; USC Norris Comprehensive Cancer Center, Los Angeles, USA.
Cao S; USC Norris Comprehensive Cancer Center, Los Angeles, USA.
Das S; Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland.
Klinger R; UCD, School of Biomolecular and Biomedical Science, Dublin, Ireland.
Betge J; Department of Medicine II, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.; German Cancer Research Center (DKFZ), Division Signaling and Functional Genomics, Heidelberg, Germany.
Murphy V; Cancer Trials Ireland, Dublin, Ireland.
Bacon O; Centre for Systems Medicine and Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.
Kay EW; Department of Pathology, Beaumont Hospital, Dublin, Ireland.
Van Grieken NCT; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
Verheul HMW; Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
Gaiser T; Institute of Pathology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Schulte N; Department of Medicine II, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Ebert MP; Department of Medicine II, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Fender B; OncoMark Ltd., NovaUCD, Belfield Innovation Park, Dublin, Ireland.
Hennessy BT; Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland.
McNamara DA; Department of Surgery, Beaumont Hospital, Dublin, Ireland.
O'Connor D; Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland.
Gallagher WM; UCD Conway Institute, University College Dublin, Dublin, Ireland.
Cremolini C; Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
Loupakis F; Oncology Unit, Istituto Oncologico Veneto, IOV-IRCCS, Padua, Italy.
Parikh A; Division of Hematology and Oncology, Massachusetts General Hospital, Boston, USA.
Mancao C; Oncology Biomarker Development, Genentech Inc., San Francisco, USA.
Ylstra B; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
Lambrechts D; VIB Vesalius Research Center, KU Leuven, Leuven, Belgium.
Lenz HJ; USC Norris Comprehensive Cancer Center, Los Angeles, USA.
Byrne AT; Centre for Systems Medicine and Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.
Prehn JHM; Centre for Systems Medicine and Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2020 Jun 17; Vol. 10 (1), pp. 9778. Date of Electronic Publication: 2020 Jun 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Validation Study
MeSH Terms:
Angiogenesis Inhibitors/*therapeutic use
Bevacizumab/*therapeutic use
Biomarkers, Tumor/*genetics
Colorectal Neoplasms/*drug therapy
Colorectal Neoplasms/*genetics
Endoplasmic Reticulum/*genetics
Proto-Oncogene Proteins p21(ras)/*genetics
Adaptor Proteins, Signal Transducing/genetics ; Aged ; Apoptosis Regulatory Proteins/genetics ; Cohort Studies ; Colorectal Neoplasms/therapy ; Combined Modality Therapy ; Endoplasmic Reticulum/metabolism ; Female ; Genetic Association Studies ; Humans ; Inflammation/genetics ; Machine Learning ; Male ; Membrane Proteins/genetics ; Middle Aged ; NLR Proteins ; Outcome and Process Assessment, Health Care/methods ; Polymorphism, Single Nucleotide ; Progression-Free Survival ; Signal Transduction
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Circulating Tumor DNA as a Preoperative Marker of Recurrence in Patients with Peritoneal Metastases of Colorectal Cancer: A Clinical Feasibility Study.
Autorzy:
Beagan JJ; Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Sluiter NR; Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Bach S; Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Eijk PP; Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Vlek SL; Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Heideman DAM; Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Kusters M; Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Pegtel DM; Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Kazemier G; Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
van Grieken NCT; Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Ylstra B; Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Tuynman JB; Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
Journal of clinical medicine [J Clin Med] 2020 Jun 04; Vol. 9 (6). Date of Electronic Publication: 2020 Jun 04.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
[ Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.
Autorzy:
van Helden EJ; Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands.
Elias SG; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Gerritse SL; Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands.
van Es SC; Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Boon E; Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Huisman MC; Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands.
van Grieken NCT; Pathology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands.
Dekker H; Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands.
van Dongen GAMS; Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands.
Vugts DJ; Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands.
Boellaard R; Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands.
van Herpen CML; Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
de Vries EGE; Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Oyen WJG; Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.; The Institute of Cancer Research and The Royal Marsden Hospital, London, UK.
Brouwers AH; Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Verheul HMW; Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands.
Hoekstra OS; Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands.
Menke-van der Houven van Oordt CW; Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands. .
Pokaż więcej
Źródło:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2020 Apr; Vol. 47 (4), pp. 849-859. Date of Electronic Publication: 2019 Nov 09.
Typ publikacji:
Clinical Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Colorectal Neoplasms*/diagnostic imaging
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Positron Emission Tomography Computed Tomography*
Biomarkers ; Cetuximab/metabolism ; Humans ; Mutation ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins p21(ras)/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome.
Autorzy:
Labots M; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Pham TV; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Honeywell RJ; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Knol JC; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Beekhof R; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
de Goeij-de Haas R; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Dekker H; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Neerincx M; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Piersma SR; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
van der Mijn JC; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
van der Peet DL; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Meijerink MR; Department of Radiology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Peters GJ; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
van Grieken NCT; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Jiménez CR; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Verheul HMW; Department of Medical Oncology, RadboudUMC, Radboud University, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2020 Feb 01; Vol. 12 (2). Date of Electronic Publication: 2020 Feb 01.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors.
Autorzy:
Meijer LL; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, VU University Amsterdam, 1081 HV, The Netherlands.
Puik JR; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, VU University Amsterdam, 1081 HV, The Netherlands.
Le Large TYS; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, VU University Amsterdam, 1081 HV, The Netherlands.; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University Amsterdam, 1081 HV, The Netherlands.; Laboratory of Experimental Oncology and Radiobiology, Amsterdam UMC, University of Amsterdam, 1105 AZ, The Netherlands.
Heger M; Department of Experimental Surgery, Amsterdam UMC, University of Amsterdam, 1105 AZ, The Netherlands.; Department of Pharmaceutics, Jiaxing University Medical College, Jiaxing 314001, Zhejiang, China.; Department of Pharmaceutics, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, 3584 CG, The Netherlands.
Dijk F; Department of Pathology, Amsterdam UMC, University of Amsterdam, 1105 AZ, The Netherlands.
Funel N; Cancer Pharmacology Lab, AIRC Start-Up Unit, Fondazione Pisana per la Scienza onlus, 56017 Pisa, Italy.
Wurdinger T; Department of Neurosurgery, Cancer Center Amsterdam, Amsterdam UMC, VU University Amsterdam, 1081 HV, The Netherlands.
Garajová I; Medical Oncology Unit, University Hospital of Parma, 43 126 Parma, Italy.
van Grieken NCT; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, VU University Amsterdam, 1081 HV, The Netherlands.
van de Wiel MA; Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam UMC, VU University Amsterdam, 1081 HV, The Netherlands.
Giovannetti E; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University Amsterdam, 1081 HV, The Netherlands. .; Cancer Pharmacology Lab, AIRC Start-Up Unit, Fondazione Pisana per la Scienza onlus, 56017 Pisa, Italy. .
Kazemier G; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, VU University Amsterdam, 1081 HV, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2019 Aug 15; Vol. 11 (8). Date of Electronic Publication: 2019 Aug 15.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
Autorzy:
Slagter AE; Department of Radiation Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Jansen EPM; Department of Radiation Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
van Laarhoven HWM; Department of Medical Oncology, Academic Medical Center Amsterdam, Meibergdreef 9, 1106 AZ, Amsterdam, The Netherlands.
van Sandick JW; Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
van Grieken NCT; Department of Pathology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Sikorska K; Statistical Department, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Cats A; Department of Gastroenterology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Muller-Timmermans P; Department of Radiation Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Hulshof MCCM; Department of Radiation Oncology, Academic Medical Center Amsterdam, Meibergdreef 9, 1106 AZ, Amsterdam, The Netherlands.
Boot H; Department of Gastroenterology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Los M; Department of Medical Oncology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.
Beerepoot LV; Department of Medical Oncology, St. Elisabeth Hospital, Hilvarenbeekse Weg 60, 5022 GC, Tilburg, The Netherlands.
Peters FPJ; Department of Medical Oncology, Zuyderland Sittard-Geleen, Dr. H. van der Hoffplein 1, 6162 BG, Sittard-Geleen, The Netherlands.
Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
van Etten B; Department of Surgery, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Hartgrink HH; Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
van Berge Henegouwen MI; Department of Surgery, Academic Medical Center Amsterdam, Meibergdreef 9, 1106 AZ, Amsterdam, The Netherlands.
Nieuwenhuijzen GAP; Department of Surgery, Catharina Hospital Eindhoven, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands.
van Hillegersberg R; Department of Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3484 CX, Utrecht, The Netherlands.
van der Peet DL; Department of Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Grabsch HI; Department of Pathology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, P Debyelaan 25, 6229 HX, Maastricht, The Netherlands.; Department of Pathology & Tumour Biology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Verheij M; Department of Radiation Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2018 Sep 10; Vol. 18 (1), pp. 877. Date of Electronic Publication: 2018 Sep 10.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Chemoradiotherapy, Adjuvant*/methods
Chemotherapy, Adjuvant*/methods
Gastrectomy*/methods
Neoadjuvant Therapy*/methods
Stomach Neoplasms/*therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Male ; Neoplasm Grading ; Neoplasm Metastasis ; Neoplasm Staging ; Quality of Life ; Stomach Neoplasms/mortality ; Stomach Neoplasms/pathology ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer.
Autorzy:
Neerincx M; Department of Medical Oncology, VUmc Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
Poel D; Department of Medical Oncology, VUmc Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
Sie DLS; Department of Pathology, VUmc Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
van Grieken NCT; Department of Pathology, VUmc Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
Shankaraiah RC; Department of Medical Oncology, VUmc Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
van der Wolf-de Lijster FSW; Department of Radiology, VUmc Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
van Waesberghe JTM; Department of Radiology, VUmc Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
Burggraaf JD; Department of Pathology, Spaarne Gasthuis, Hoofddorp, The Netherlands.
Eijk PP; Department of Pathology, VUmc Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
Verhoef C; Department of Surgical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
Ylstra B; Department of Pathology, VUmc Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
Meijer GA; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van de Wiel MA; Department of Epidemiology and Biostatistics, VUmc Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.; Department of Mathematics, VU University, Amsterdam, The Netherlands.
Buffart TE; Department of Medical Oncology, VUmc Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
Verheul HMW; Department of Medical Oncology, VUmc Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2018 Aug 03; Vol. 13 (8), pp. e0201809. Date of Electronic Publication: 2018 Aug 03 (Print Publication: 2018).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Colorectal Neoplasms/*diagnosis
Colorectal Neoplasms/*therapy
MicroRNAs/*metabolism
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/therapeutic use ; Area Under Curve ; Biomarkers, Tumor/metabolism ; Cohort Studies ; Colorectal Neoplasms/pathology ; Disease Progression ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Middle Aged ; Prognosis ; ROC Curve
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 23

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies